{{Rsnum
|rsid=564148
|Gene=CSMD2
|Chromosome=1
|position=33708220
|Orientation=plus
|GMAF=0.09045
|Gene_s=CSMD2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 1.8 | 25.0 | 73.2
| HCB | 1.5 | 22.1 | 76.5
| JPT | 0.0 | 19.6 | 80.4
| YRI | 0.0 | 3.4 | 96.6
| ASW | 0.0 | 5.3 | 94.7
| CHB | 1.5 | 22.1 | 76.5
| CHD | 1.9 | 23.4 | 74.8
| GIH | 1.0 | 15.8 | 83.2
| LWK | 0.0 | 1.8 | 98.2
| MEX | 0.0 | 5.2 | 94.8
| MKK | 0.0 | 1.3 | 98.7
| TSI | 0.0 | 31.4 | 68.6
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=22952603
  |Trait=Response to amphetamines
  |Title=Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13).
  |RiskAllele=
  |Pval=9E-6
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA}}